About us

Founders

Prof. Rafael Kramann
Prof. Rebekka Schneider
Portrait of Dr. Michael Rheinnecker, CEO Sequantrix
Dr. Michael Rheinnecker
Dr. Sikander Hayat
Dr. Konrad Hoeft

Board

David Schilansky
Prof. Rafael Kramann
Dr. Mark Wolters

Team

Connor Gautron
Technician, Target Validation
Dina Zelener
Technician, Target Validation
Dr. Felix Schreibing
Team Leader Biocomputing
Filippo Favarato
Technician, Target Validation
Dr. Jitske Jansen
Group Leader Target Validation
Dr. Maurice Halder
Scientist, Target Validation
Portrait of Dr. Michael Rheinnecker, CEO Sequantrix
Dr. Michael Rheinnecker
Co-Founder & CEO
Dr. Niclas Flosdorf
Scientist, Target Validation
Sanyal Ritabrata
Scientist, Biocomputing
Suchanda Bhattacharyya
Scientist, Biocomputing
Ursula Förster
Senior Technician, Target Validation

History

SequantrixTM is a spin-out of the Uniklinik RWTH Aachen, Germany and is based on decade-long research and clinical expertise of Prof. Rafael Kramann and Prof. Rebekka Schneider in the field of fibrosis.

The Uniklinik RWTH Aachen has supported the spin-out process through its technology transfer organisation RWTH Innovation GmbH by transferring assets and IP and continues to keep close ties through joint research projects.